Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.53 - $40.28
Previous CloseN/A
Volume41.90K
Average Volume (3M)705.52K
Market Cap
$1.81B
Enterprise Value$1.62B
Total Cash (Recent Filing)$23.74M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)24.6
Beta0.78
Next Earnings
May 13, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding55,814,495
10 Day Avg. Volume574,138
30 Day Avg. Volume705,517
Financial Highlights & Ratios
PEG Ratio0.00477
Price to Book (P/B)N/A
Price to Sales (P/S)2.71
Price to Cash Flow (P/CF)10.10
P/FCF Ratio10.10
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda9.79
Forecast
1Y Price Target
$38.80Price Target Upside18.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Supernus Pharmaceuticals News
PremiumCompany Announcements
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Supernus Pharmaceuticals Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Supernus Pharmaceuticals Updates Executive Compensation Packages---
Bulls Say, Bears Say
Bulls Say
Market Growth PotentialThe large ADHD market can support multiple branded non-stimulants, suggesting room for Qelbree's growth.
Patent ExtensionQelbree's '338 patent has been extended by 2 years to 2035, which buys time for management to introduce more pipeline assets.
Product LaunchThe apomorphine SubQ pump for Parkinson's is expected to launch, offering a significant market opportunity.
Bears Say
Clinical Study ResultFor SPN-820 in depression, the Phase IIb study showed a modest result that was not statistically significant, questioning its impact.
Stock Rating DowngradeDisappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.
Trial Data AnalysisThe trial for SPN-820 is on 'pause' as the company continues to analyze more data from the study.
---
Ownership Overview
4.12% Insiders
31.78% Mutual Funds
28.93% Other Institutional Investors
3.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $25.53 and its highest was $40.28 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $1.81B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported $0.746 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.226.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.36.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 55,814,495 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.746 in its last earnings report, beating expectations of $0.52. Following the earnings report the stock price went down -2.743%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
---
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.80 (18.51% Upside)
$38.80 (18.51% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 80%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 261.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $505.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.01%
12-Months-Change
Fundamentals
Return on Equity
7.55%
Trailing 12-Months
Asset Growth
6.52%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
---
SUPN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in core products and financial performance, FDA approvals, and a robust cash position. However, challenges include declines in legacy product sales, unfavorable study results for SPN-820, and conservative 2025 guidance. The positive aspects slightly outweigh the negative trends.Read More>---
SUPN Stock 12 Month Forecast
Average Price Target
$38.80
▲(18.51% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Jazz Pharmaceuticals
―
Neurocrine
―
Heron Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering SUPN
1 Year
---